News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
Presentation ACC 2025 STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes Presenter: Marc P. Bonaca March 29, 2025
News Daily News ACC 2025 STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients L.A. McKeown March 29, 2025
News Conference News ACC 2018 Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS Michael O'Riordan March 12, 2018
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017